In murine models, treatment with MOTS-c improves insulin responsiveness, counteracts obesity induced by high-fat feeding, and reduces β-cell damage driven by autoimmune mechanisms via regulation of mTORC1 activity [87,88]. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.